awmsg logo



oseltamivir (Tamiflu®)


Reference No. 2800

Publication date:
01/04/2016


Appraisal information

oseltamivir (Tamiflu®) 30 mg capsule
oseltamivir (Tamiflu®) 45 mg capsule
oseltamivir (Tamiflu®) 75 mg capsule
oseltamivir (Tamiflu®) 6 mg/ml powder for oral suspension


Company: Roche Products Ltd
BNF category: Infections
NMG meeting date: 20/01/2016
AWMSG meeting date: 24/02/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0316
Ministerial ratification: 24/03/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Oseltamivir (Tamiflu®) is recommended for use within NHS Wales for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download